299 related articles for article (PubMed ID: 24339143)
41. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage.
Taguchi Y; Yamamoto M; Yamate T; Lin SC; Mocharla H; DeTogni P; Nakayama N; Boyce BF; Abe E; Manolagas SC
Proc Assoc Am Physicians; 1998; 110(6):559-74. PubMed ID: 9824538
[TBL] [Abstract][Full Text] [Related]
42. GP130/OSMR is the only LIF/IL-6 family receptor complex to promote osteoblast differentiation of calvaria progenitors.
Malaval L; Liu F; Vernallis AB; Aubin JE
J Cell Physiol; 2005 Aug; 204(2):585-93. PubMed ID: 15751050
[TBL] [Abstract][Full Text] [Related]
43. [Development, physiology, and cell activity of bone].
de Baat P; Heijboer MP; de Baat C
Ned Tijdschr Tandheelkd; 2005 Jul; 112(7):258-63. PubMed ID: 16047964
[TBL] [Abstract][Full Text] [Related]
44. Boning up on ephrin signaling.
Mundy GR; Elefteriou F
Cell; 2006 Aug; 126(3):441-3. PubMed ID: 16901775
[TBL] [Abstract][Full Text] [Related]
45. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling.
Walker EC; McGregor NE; Poulton IJ; Pompolo S; Allan EH; Quinn JM; Gillespie MT; Martin TJ; Sims NA
J Bone Miner Res; 2008 Dec; 23(12):2025-32. PubMed ID: 18665789
[TBL] [Abstract][Full Text] [Related]
46. Osteoclasts are present in gp130-deficient mice.
Kawasaki K; Gao YH; Yokose S; Kaji Y; Nakamura T; Suda T; Yoshida K; Taga T; Kishimoto T; Kataoka H; Yuasa T; Norimatsu H; Yamaguchi A
Endocrinology; 1997 Nov; 138(11):4959-65. PubMed ID: 9348227
[TBL] [Abstract][Full Text] [Related]
47. Extracellular matrix networks in bone remodeling.
Alford AI; Kozloff KM; Hankenson KD
Int J Biochem Cell Biol; 2015 Aug; 65():20-31. PubMed ID: 25997875
[TBL] [Abstract][Full Text] [Related]
48. Low bone mass and changes in the osteocyte network in mice lacking autophagy in the osteoblast lineage.
Piemontese M; Onal M; Xiong J; Han L; Thostenson JD; Almeida M; O'Brien CA
Sci Rep; 2016 Apr; 6():24262. PubMed ID: 27064143
[TBL] [Abstract][Full Text] [Related]
49. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways.
Sims NA; Jenkins BJ; Quinn JM; Nakamura A; Glatt M; Gillespie MT; Ernst M; Martin TJ
J Clin Invest; 2004 Feb; 113(3):379-89. PubMed ID: 14755335
[TBL] [Abstract][Full Text] [Related]
50. Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling.
Edwards JR; Perrien DS; Fleming N; Nyman JS; Ono K; Connelly L; Moore MM; Lwin ST; Yull FE; Mundy GR; Elefteriou F
J Bone Miner Res; 2013 Apr; 28(4):960-9. PubMed ID: 23172686
[TBL] [Abstract][Full Text] [Related]
51. Runx1-mediated regulation of osteoclast differentiation and function.
Soung do Y; Kalinowski J; Baniwal SK; Jacome-Galarza CE; Frenkel B; Lorenzo J; Drissi H
Mol Endocrinol; 2014 Apr; 28(4):546-53. PubMed ID: 24606124
[TBL] [Abstract][Full Text] [Related]
52. Skeletal characterization of an osteoblast-specific vitamin D receptor transgenic (ObVDR-B6) mouse model.
Triliana R; Lam NN; Sawyer RK; Atkins GJ; Morris HA; Anderson PH
J Steroid Biochem Mol Biol; 2016 Nov; 164():331-336. PubMed ID: 26343450
[TBL] [Abstract][Full Text] [Related]
53. Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures.
Movérare-Skrtic S; Henning P; Liu X; Nagano K; Saito H; Börjesson AE; Sjögren K; Windahl SH; Farman H; Kindlund B; Engdahl C; Koskela A; Zhang FP; Eriksson EE; Zaman F; Hammarstedt A; Isaksson H; Bally M; Kassem A; Lindholm C; Sandberg O; Aspenberg P; Sävendahl L; Feng JQ; Tuckermann J; Tuukkanen J; Poutanen M; Baron R; Lerner UH; Gori F; Ohlsson C
Nat Med; 2014 Nov; 20(11):1279-88. PubMed ID: 25306233
[TBL] [Abstract][Full Text] [Related]
54. Overexpression of Gα
Zhang L; Sugamori KS; Claridge C; Dela Cruz A; Grynpas MD; Mitchell J
J Bone Miner Res; 2017 Nov; 32(11):2171-2181. PubMed ID: 28727179
[TBL] [Abstract][Full Text] [Related]
55. Interleukin-11 receptor signaling is required for normal bone remodeling.
Sims NA; Jenkins BJ; Nakamura A; Quinn JM; Li R; Gillespie MT; Ernst M; Robb L; Martin TJ
J Bone Miner Res; 2005 Jul; 20(7):1093-102. PubMed ID: 15940362
[TBL] [Abstract][Full Text] [Related]
56. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
[TBL] [Abstract][Full Text] [Related]
57. Expression of the type 1 lysophosphatidic acid receptor in osteoblastic cell lineage controls both bone mineralization and osteocyte specification.
Alioli CA; Demesmay L; Laurencin-Dalacieux S; Beton N; Farlay D; Follet H; Saber A; Duboeuf F; Chun J; Rivera R; Bouvard D; Machuca-Gayet I; Salles JP; Gennero I; Peyruchaud O
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Aug; 1865(8):158715. PubMed ID: 32330664
[TBL] [Abstract][Full Text] [Related]
58. High bone mass in mice lacking Cx37 because of defective osteoclast differentiation.
Pacheco-Costa R; Hassan I; Reginato RD; Davis HM; Bruzzaniti A; Allen MR; Plotkin LI
J Biol Chem; 2014 Mar; 289(12):8508-20. PubMed ID: 24509854
[TBL] [Abstract][Full Text] [Related]
59. New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gp130.
Manolagas SC; Bellido T; Jilka RL
Int J Immunopharmacol; 1995 Feb; 17(2):109-16. PubMed ID: 7657404
[TBL] [Abstract][Full Text] [Related]
60. Mef2c deletion in osteocytes results in increased bone mass.
Kramer I; Baertschi S; Halleux C; Keller H; Kneissel M
J Bone Miner Res; 2012 Feb; 27(2):360-73. PubMed ID: 22161640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
